Alebund Pharmaceutical
Alebund Pharmaceutical raises $75M Series C at $500M valuation
Quick Facts
Alebund Pharmaceutical: Series C Funding Round
Alebund Pharmaceutical has successfully raised $75M in Series C funding, reaching a valuation of $500M.
Company Overview
Renal disease therapeutics
Funding Details
The Series C round was led by Kingray Capital, with participation from Yangzhou Guojin.
Company Information
- Headquarters: Shanghai, China
- Founded: 2018
- Employees: 150+
- Category: HealthTech
Investment
Alebund Pharmaceutical plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Kingray Capital: Verified investor in Series C
- Yangzhou Guojin: Verified investor in Series C
Key Investors
About the Author
Related Company Reports
AccelerateStack Platform raises $75M Series C at $226M valuation
AccelerateStack Platform secures $75M in Series C funding led by Intel Capital, reaching $226M valuation as it accelerates growth in the healthtech sector.
DermaSensor raises $16M Series B at $85M valuation
DermaSensor raises $16M in Series B at $85M valuation. AI-powered skin cancer screening device for early detection...
Devoted Health Partners Headquarters - Office Location & Address
Discover Devoted Health Partners's headquarters at 100 2nd Ave, Waltham, MA 02451. Medicare Advantage insurance. Learn about the office facilities and work environment.
